Virtuos gives the hospital considerable logistical and financial benefits along with enhanced shipping, storage, and operating room efficiency
Orthofix announces commercial release and first patient implant of its Virtuos Lyograft. (Credit: Business Wire/ Orthofix Medical Inc.)
US-based medical device company Orthofix Medical announced the commercial release and the first patient implant of its Virtuos Lyograft.
Virtuos Lyograft is a shelf-stable and complete autograft substitute intended for spine and orthopaedic procedures.
The allograft is prepared by MTF Biologics through a unique process that keeps all of the biological elements required for bone repair within the transplant.
Orthofix said that Virtuos is delivered in a mouldable, ready-to-use state at room temperature.
Virtuos gives the hospital considerable logistical and financial benefits along with enhanced shipping, storage, and operating room efficiency.
The device is sent and stored at ambient temperature, which removes the need for vast amounts of dry ice, Styrofoam containers, and freezer storage.
This allows for flexible transportation choices and less packing, intending to lower carbon emissions.
Orthofix Global Spine president Kevin Kenny said: “The Virtuos Lyograft provided through our exclusive partnership with MTF Biologics is at the forefront of allograft technology.
“Processed through a proprietary preservation method, Virtuos provides the best of both worlds.
“It delivers a high-quality shelf-stable bone graft with the clinical performance and superior handling that clinicians desire, as well as streamlined logistics for storage and preparation for the hospital.”
The Virtuos Lyograft is an addition to Orthofix’s extensive line of biologics via its collaboration with MTF Biologics, which already includes the Trinity Elite, Trinity Evolution, FiberFuse Advanced and FiberFuse Strip allografts, AlloQuent structural allograft, and Legacy DBM.
The company promotes and sells the Opus BA bioactive bone graft, Opus Mg Set bone void filler, Opus osteoconductive matrix, and the O-Genesis graft delivery system in addition to MTF Biologic solutions.
MTF Biologics is a non-profit organisation operating on a worldwide scale that advances research, cares for patients, and saves and heals lives.
It offers services, resources, and knowledge to those who depend on tissue and organ transplants, healthcare professionals, doctors, and scientists, as well as donors who donate the gift of donation.